NBIO - Nascent Biotech posts Pritumumab COVID-19 In-Vitro study results

Nascent Biotech ([[NBIO]] +19.2%) announces the publication of In-Vitro study results from its research collaboration with Syracuse University, with data arising from this research suggesting that its Pritumumab antibody blocks uptake of COVID-19, reducing the spread of the infection in the body.The company said that the data showed that Pritumumab successfully blocked 80% of viral entry into cells. Based on these results, PTB will be advanced to laboratory-based animal studies, it said."These results may further suggest the efficacy of PTB administered in therapeutic combination with other drugs targeting different pathways," CEO Sean Carrick said.

For further details see:

Nascent Biotech posts Pritumumab COVID-19 In-Vitro study results